Shares of Fresenius Medical Care AG (NYSE:FMS) hit a new 52-week high during trading on Monday . The company traded as high as $45.89 and last traded at $45.65, with a volume of 74,386 shares changing hands. The stock had previously closed at $45.65.

A number of brokerages have commented on FMS. Sanford C. Bernstein began coverage on shares of Fresenius Medical Care AG in a research report on Monday, April 11th. They set an “outperform” rating on the stock. DZ Bank AG reaffirmed a “sell” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, May 10th. Jefferies Group raised shares of Fresenius Medical Care AG from an “underperform” rating to a “hold” rating in a research report on Friday, July 8th. Zacks Investment Research raised shares of Fresenius Medical Care AG from a “sell” rating to a “hold” rating in a research report on Wednesday, May 4th. Finally, Royal Bank Of Canada reissued a “hold” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, May 24th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $42.50.

The firm has a 50 day moving average price of $43.10 and a 200-day moving average price of $42.95. The firm has a market cap of $27.88 billion and a P/E ratio of 26.56.

Fresenius Medical Care AG (NYSE:FMS) last issued its earnings results on Tuesday, May 3rd. The company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.33. The business earned $4.21 billion during the quarter, compared to analysts’ expectations of $4.25 billion. During the same quarter in the previous year, the business earned $0.69 EPS. Fresenius Medical Care AG’s revenue for the quarter was up 6.2% compared to the same quarter last year. Equities research analysts expect that Fresenius Medical Care AG will post $2.03 earnings per share for the current fiscal year.

Other institutional investors have modified their holdings of the company. Morgan Stanley boosted its position in shares of Fresenius Medical Care AG by 20.5% in the fourth quarter. Morgan Stanley now owns 685,338 shares of the company’s stock worth $28,675,000 after buying an additional 116,653 shares during the last quarter. WBI Investments Inc. purchased a new position in Fresenius Medical Care AG during the fourth quarter worth about $2,249,000. Bank of Montreal Can boosted its position in Fresenius Medical Care AG by 60.0% in the fourth quarter. Bank of Montreal Can now owns 56,700 shares of the company’s stock worth $2,373,000 after buying an additional 21,264 shares during the last quarter. US Bancorp DE boosted its position in Fresenius Medical Care AG by 4.0% in the fourth quarter. US Bancorp DE now owns 274,935 shares of the company’s stock worth $11,503,000 after buying an additional 10,479 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Fresenius Medical Care AG by 3.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 107,376 shares of the company’s stock worth $4,493,000 after buying an additional 3,694 shares during the last quarter.

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.